市场调查报告书
商品编码
1394980
盐酸去氧肾上腺素市场 -按应用(鼻充血、感冒、低血压、过敏反应、眼部疾病)、模式(内部、合约)、用途(人类、兽医)全球预测,2023 - 2032Phenylephrine Hydrochloride Market - By Application (Nasal Decongestion, Cold, Hypotension, Allergic Reaction, Eye Diseases), Mode (In-house, Contract), Use (Human, Veterinary) Global Forecast, 2023 - 2032 |
在全球过敏和环境敏感性数量激增的推动下,盐酸去氧肾上腺素市场规模预计在 2023 年至 2032 年期间以 7.7% 的CAGR扩大。随着越来越多的人对环境因素产生过敏反应,对含有盐酸去氧肾上腺素的有效减充血药物的需求正在上升。盐酸去氧肾上腺素能够缓解与过敏反应相关的鼻塞,因此在过敏缓解製剂的生产中得到越来越多的采用。
此外,正在进行的旨在改进含有盐酸去氧肾上腺素的药物的配方和给药方法的研发工作预计将推动市场成长。举个例子,2023 年5 月,Eyenovia, Inc. 的Mydcombi 获得美国FDA 批准,这是一种1%/2.5% 托吡卡胺和盐酸去氧肾上腺素眼部喷雾剂,用于瞳孔散大的诊断程序和需要短期瞳孔的扩张。
盐酸去氧肾上腺素产业按应用、模式、用途和地区细分。
根据模式,预计 2023 年至 2032 年合约製造领域的市占率CAGR将达到 7.9%。合约製造为製药公司提供了简化生产和优化成本的策略方法。此外,将製造流程外包给专业合约製造商可确保高效生产、品质合规性和可扩展性。这种模式还允许製药公司专注于研发活动,同时利用合约製造商的专业知识,及时、经济高效地生产基于盐酸去氧肾上腺素的药物。
在应用方面,来自过敏反应领域的盐酸去氧肾上腺素产业在2022年产生了可观的收入,并有望在2023年至2032年期间实现7%的成长率。这可归因于用于缓解与过敏反应相关的鼻塞的药物的使用增加。过敏、环境因素和生活方式改变的盛行率不断上升,也增加了对含有盐酸去氧肾上腺素的药品的需求,从而推动了该领域的成长。
从地区来看,在製药和医疗保健产业不断扩大的推动下,亚太地区盐酸去氧肾上腺素市场预计 2023 年至 2032 年CAGR为 8.1%。呼吸系统疾病盛行率的上升和对减充血药物的持续需求导致对盐酸去氧肾上腺素的需求增加。此外,亚太地区主要国家人口的成长、都市化和生活方式的变化正在推动人们对非处方药的偏好,进一步提振该地区的产业前景。
Phenylephrine Hydrochloride Market size is poised to expand at 7.7% CAGR from 2023-2032, driven by the surge in the number of allergies and environmental sensitivities worldwide. With more individuals experiencing allergic reactions to environmental factors, the demand for effective decongestant medications containing phenylephrine hydrochloride is rising. The ability to alleviate nasal congestion associated with allergic response is contributing to the increasing adoption of phenylephrine hydrochloride in the production of allergy relief formulations.
Furthermore, the ongoing R&D efforts aimed at improving formulations and delivery methods for medications containing phenylephrine hydrochloride are projected to propel market growth. To cite an instance, in May 2023, Eyenovia, Inc. received approval from the U.S. FDA for its Mydcombi, a 1%/2.5% tropicamide and phenylephrine hydrochloride ocular spray used in mydriasis for diagnostic procedures and in cases with desired short-term pupil dilation.
The phenylephrine hydrochloride industry is segmented into application, mode, use, and region.
As per mode, the market share from the contract manufacturing segment is anticipated to record 7.9% CAGR from 2023-2032. Contract manufacturing offers pharmaceutical companies a strategic approach to streamline production and optimize costs. Additionally, outsourcing the manufacturing processes to specialized contract manufacturers ensures efficient production, quality compliance, and scalability. This mode also allows pharmaceutical firms to focus on R&D activities while leveraging the expertise of contract manufacturers for timely and cost-effective production of phenylephrine hydrochloride-based medications.
In terms of application, the phenylephrine hydrochloride industry from the allergic reaction segment generated substantial revenue in 2022 and is poised to depict 7% growth rate from 2023 to 2032. This can be attributed to increasing use in medications for relieving nasal congestion associated with allergic reactions. The rising prevalence of allergies, environmental factors, and the changing lifestyles is also surging the need for pharmaceuticals containing phenylephrine hydrochloride, thereby fueling the segment growth.
Regionally, the Asia Pacific phenylephrine hydrochloride market is anticipated to exhibit 8.1% CAGR from 2023-2032 driven by the expanding pharmaceutical and healthcare sectors. The rising prevalence of respiratory conditions and the incessant need for decongestant medications is leading to the increased demand for phenylephrine hydrochloride. Additionally, the rising population, urbanization, and the changing lifestyles across major APAC countries are fueling the preference for over-the-counter medications, further boosting the regional industry outlook.